Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for MDT, PLTR and BCS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Friday, October 14, 2022 12:15 PM
Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / October 14, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

MDT Shareholders Click Here: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=32669&wire=1
PLTR Shareholders Click Here: https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=32669&wire=1
BCS Shareholders Click Here: https://www.zlk.com/pslra-1/barclays-plc-information-request-form?prid=32669&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Friday, October 14, 2022, Press release picture

Medtronic plc (NYSE:MDT)

This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.
Lead Plaintiff Deadline : November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=32669&wire=1

According to the filed complaint, (1) Medtronic's product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of the Company's misconduct, the U.S. Food and Drug Administration would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company's need to improve its quality control systems, would negatively affect the Company's financial performance and cause Medtronic to fall further behind its competitors; and (6) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Palantir Technologies Inc. (NYSE:PLTR)

PLTR Lawsuit on behalf of: investors who purchased November 9, 2021 - May 6, 2022
Lead Plaintiff Deadline : November 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=32669&wire=1

According to the filed complaint, during the class period, Palantir Technologies Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Palantir's investments in marketable securities were having a significant negative impact on the Company's earnings per share ("EPS") results; (ii) Palantir overstated the sustainability of its government segment's growth and revenues; (iii) Palantir was experiencing a significant slowdown in revenue growth, particularly among its government customers, despite ongoing global conflicts and market disruptions; (iv) as a result of all the foregoing, the Company was likely to miss consensus estimates for its first quarter 2022 EPS and second quarter 2022 sales outlook; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Barclays PLC (NYSE:BCS)

This lawsuit is on behalf of persons who purchased or otherwise acquired Barclays American Depositary Receipts on a U.S. open market between February 18, 2021 and March 25, 2022.
Lead Plaintiff Deadline : November 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/barclays-plc-information-request-form?prid=32669&wire=1

According to the filed complaint, a) as of December 31, 2020 and February 18, 2021, Barclays had a material weakness in its internal control environment due to the fact that the over-issuance had occurred and was not immediately identified; and b) they failed to disclose that as of February 18, 2021 (i) Barclays Bank PLC ("BBPLC") had and was selling unregistered securities in excess of the amounts registered by the August 2019 shelf registration statement, (ii) BBPLC was violating U.S. securities laws and/or the U.S. Securities and Exchange Commission regulations, subjecting Barclays to legal liability, and (iii) BBPLC was required to conduct a rescission offer for those unregistered securities.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Class Action
Back to newsroom
Back to Newsroom